FDA Updates Temozolomide Prescribing Information in Brain Cancer

News
Article

Prescribing information has been updated to include temozolomide as adjuvant treatment for adult patients with newly diagnosed anaplastic astrocytoma or refractory anaplastic astrocytoma.

The updated label now includes the use of temozolomide as adjuvant treatment for adult patients with newly diagnosed anaplastic astrocytoma and for adult patients with refractory anaplastic astrocytoma.

The updated label now includes the use of temozolomide as adjuvant treatment for adult patients with newly diagnosed anaplastic astrocytoma and for adult patients with refractory anaplastic astrocytoma.

The FDA has approved updated labeling for temozolomide (Temodar) in brain cancer, according to a press release from the organization.1

The updated label now includes the use of temozolomide as adjuvant treatment for adult patients with newly diagnosed anaplastic astrocytoma and for adult patients with refractory anaplastic astrocytoma.

The press release noted that the approved indication for temozolomide in adult patients with newly diagnosed glioblastoma, given concomitantly with radiotherapy and as maintenance therapy, remains the same. Temozolomide was originally approved by the FDA under this indication in March 2005.2 Temozolomide was approved for intravenous use in 1999.3

The label update also includes the dosing regimen for patients with newly diagnosed glioblastoma and refractory anaplastic astrocytoma. For temozolomide given as capsules, there is an increase of exposure risk from opened capsules. Additionally, the patient counseling information section has been revised.

The updated labeling comes under the Project Renewal program with the Oncology Center of Excellence. This program is designed to revise label information for older drugs in the oncology space so that all information is up-to-date and relevant.

References

  1. FDA approves new and updated indications for temozolomide under Project Renewal. News release. FDA. September 14, 2023. Accessed September 14, 2023. https://bit.ly/3LnH9fS
  2. Cohen MH, Johnson JR, Pazdur R. Food and Drug Administration Ddug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res. 2005;11(19 Pt 1):6767-6771. doi:10.1158/1078-0432.CCR-05-0722
  3. Temozolomide. Prescribing information. Merck; 2023. Accessed September 14, 2023. https://bit.ly/46uUH1p
Related Videos
ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.
Related Content
The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.

FDA Approves Tovorafenib for Relapsed/Refractory Low-Grade Glioma

April 23rd 2024
Article

The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.

Javier Orozco-Mera, MD, FACS, MSc, discusses signaling pathways and molecular mechanisms involved in the relapse of glioblastoma.

Oncology-On-The-Go Podcast: Signaling Pathways in Glioblastoma Relapse

May 1st 2023
Podcast

Javier Orozco-Mera, MD, FACS, MSc, discusses signaling pathways and molecular mechanisms involved in the relapse of glioblastoma.

First-in-patient findings support AZD1390 as a potential radiosensitizer during the management of glioblastoma.

AZD1390/Radiation Yields Encouraging Efficacy, Safety in Glioblastoma

April 9th 2024
Article

First-in-patient findings support AZD1390 as a potential radiosensitizer during the management of glioblastoma.

Promising Glioma Therapy Options

Promising Glioma Therapy Options

December 21st 2018
Podcast

Dr. James Perry speaks with Cancer Network about glioma therapy options and the future of brain cancer treatment.

Findings from a phase 1b trial support the tolerability and potential survival benefit of CAN-3110 as a treatment for patients with recurrent high-grade glioma.

CAN-3110 Earns FDA Fast Track Designation in Recurrent High-Grade Glioma

February 13th 2024
Article

Findings from a phase 1b trial support the tolerability and potential survival benefit of CAN-3110 as a treatment for patients with recurrent high-grade glioma.

Eflornithine, which was approved in adult and pediatric patients with high-risk neuroblastoma, was assessed in an externally controlled trial comparing results in both Study 3b and Study ANBL0032.

Eflornithine Is Approved by the FDA for High-Risk Neuroblastoma

December 13th 2023
Article

Eflornithine, which was approved in adult and pediatric patients with high-risk neuroblastoma, was assessed in an externally controlled trial comparing results from Study 3b and Study ANBL0032.